BioSpace News Archive

In response to the rapid market expansion of oligonucleotide therapeutics that have potential to treat both common and intractable diseases, Nitto Denko Corporation (Headquarters: Osaka; President: Hideo Takasaki; referred to hereafter as “Nitto”) will invest approximately 25 billion Japanese yen in Nitto Denko Avecia Inc.

Data-Driven Research Presented at Academy of Managed Care Pharmacy (AMCP), ISPOR Annual Meeting and Key Spring Conferences Powered by Inovalon’s MORE2 Registry® Dataset

AbbVie (NYSE: ABBV) will announce its first-quarter 2021 financial results on Friday, April 30, 2021 , before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time .

Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced that they have enrolled the first patient in their pivotal Phase 1/2 clinical study of GC007g

Bausch Health Companies Inc. announced that it and certain of its affiliates have entered into a definitive agreement to sell all of their equity interests in Amoun Pharmaceutical Company S.A.E. to Abu-Dhabi based ADQ, one of the region’s largest holding companies, for total gross consideration of approximately U.S. $740 million, subject to certain adjustments.

Frontier Medicines, Corp., a precision medicine company drugging challenging protein targets to develop breakthrough medicines that change the course of human diseases, today announced the appointment of Gregory Chow as chief financial officer.

BIOREM Inc. (TSXV: BRM) (“Biorem” or “the Company”) today announced its results for the three and twelve-month periods ended December 31, 2020.

Union Acquisition Corp. II announced execution of a definitive business combination agreement along with a fully committed PIPE financing agreement with Procaps Group its newly created wholly-owned subsidiary, Procaps Group, S.A., and the Company’s wholly-owned Cayman Island subsidiary.

BioTools Innovator, a new accelerator program developed by the team behind MedTech Innovator, the world’s largest accelerator of medical device startups, announced its launch today.

NeuroPace, Inc. today announced that the company has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA) for the potential use of its RNS® System to treat idiopathic generalized epilepsy (IGE), which constitutes as many as one third of all epilepsies and is understood to have a strong underlying genetic basis.